Assessment of the Efficacy of Ocular Dipyridamole in the Treatment of Dry Eye Symptomology in Subjects With Pterygium

Dry Eye Syndromes Clinical Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT02782260
• Other study ID #: 0064-16-WOMC
• Status: Not yet recruiting
• Phase: Phase 2
• First received: May 10, 2016
• Last updated: May 24, 2016
• Start date: July 2016
• Est. completion date: January 2018

Study information

• Verified date: May 2016
• Source: Ariel University
• Contact: n/a
• Is FDA regulated: No
• Health authority: Israel: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

Subjects with pterygium and associated dry eye symptoms (DES) are randomized into an active cohort (receiving ocular administration of Dipyridamole) or placebo cohort (ocular administration of vehicle). Monthly follow up is conducted for 12 months. Testing conducted at follow up will assess dry eye / pterygium symptoms and endpoints and review the efficacy of the intervention.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 40
• Est. completion date: January 2018
• Est. primary completion date: October 2017
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Able to provide informed consent.

• Ineligible or refused surgical excision, or had recurrence of pterygium following surgical excision

• Able to follow the study instructions, including application of the study product

• Agreement not to change the type of lubricating eye drops used (if any) during their participation in the study.

• Assessed as having at least pterygium stage 0-1 (pinguecula) based on Johnston, Williams & Sheppard's classification for pterygium

• Concomitant dry eye symptoms, as determined by one or more of the following Subject interview (modified Ocular Surface Disease Index test), Tearing, Itch / foreign body sensation, Positive Fluorescein test, Positive TBUT test, Positive Tear meniscus test

Exclusion Criteria:

• Inability to provide informed consent

• Dry eye due to other factors

• Known lacrimal obstruction

• Contact lens wearers

• Non-corrected refraction

• Allergy or sensitivity to dipyridamole or excipients

• Use of dipyridamole in the last 6 months

• Other eye conditions (i.e. active ocular infection, herpes keratitis in last 6 months, corneal disorder abnormality excluding pterygium, history of ocular acne rosacea, blepharitis) which would impact results

• Diagnosis of ALS (Amyotrophic lateral sclerosis)

• Existing conditions which are contraindicated or precaution in use of dipyridamole or excipients

• Use of eye drops (other than ocular lubricants)

• Pregnant or breastfeeding

• Inability to apply the medical product or follow the study procedures

• Anything that the PI thinks would impact the trial

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Dry Eye Syndromes
• Keratoconjunctivitis Sicca
• Pterygium

Intervention

Drug:
• Dipyridamole

• Placebo

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Ariel University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Assess the changes in dry eye parameters via a change in tear secretion rate	Change in the tear secretion rate will be defined by successful change in parameters of ONE of the following testing methods compared to baseline: Fluorescein - Improvement of one of the quadrants sufficient to change the severity rating; TBUT (Tear Breakup time) - Decreased by at least 1 second; Tear meniscus test - Increase of at least 0.2mm	6 months	No
Primary	Assess the changes in dry eye parameters via reduction in dry eye symptomology.	Reduction in dry eye symptomology will be defined as ONE of the following relative to baseline, determined by subject feedback; An improvement in questionnaire scores; Specified improvement in blurred vision grading; Specified improvement in tearing grading; Specified improvement in itch / foreign body (grittiness) sensation grading.	6 months	No
Secondary	A minimum significant reversion of pterygia relative to baseline or cessation of growth of pterygium	Minimum significant reversion will be defined as a decrease in vascularisation, or a measurable decrease from baseline of OCT (Ocular Coherence Tomography) measured parameters (height or width).	12 months	No